Contact
searchSearch
HMP Global
Login

June 2016

From the Field
A Method of Deriving Estimates of Health State Utilities for Patients With Metastatic Breast Cancer
06/20/2016
Gabriel Tremblay, DBA, MSc; Stacie Hudgens, MA, MSc; Andrew Briggs, DPhil, MSc; Andrew J. Lloyd, DPhil; Anna Forsythe, PharmD, MBA, MSc
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
...
06/20/2016
Journal of Clinical Pathways
Research Reports
SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors
06/20/2016
Brooke Hoverman; Stephanie Trenkner, BS; Carlena Magley, BS; Hilary Biddle, RN, BSN, CCRC; Nancy Ehmke, RN, MN, AOCN; Breck Hunnicutt, RN, BSN, CCRC; Christina Zelt, RN, MSN
Abstract:As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their journey....
Abstract:As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their journey....
...
06/20/2016
Journal of Clinical Pathways
Pharma Insights
Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer's Treatments?
06/20/2016
Rick Lifsitz, MBA; Larry Blandford, PharmD
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Beyond Medication Class: How Specific Should the Clinical Pathway Get?
06/20/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD; Taha Khan, PharmD, RPh
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
...
06/20/2016
Journal of Clinical Pathways
Interview
The Potentials and Barriers of Precision Medicine in Oncology
06/20/2016
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In...
06/20/2016
Journal of Clinical Pathways
Interview
Reducing Waste in Oncology Drug Use
06/20/2016
According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs associated...
According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs associated...
...
06/20/2016
Journal of Clinical Pathways
Conference Coverage
Perceptions of ICER Reports and Health Technology Assessments in the United States
06/20/2016
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER...
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER...
...
06/20/2016
Journal of Clinical Pathways
Conference Coverage
2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting
06/20/2016
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
Bundled Payments Model Utilizing Clinical Pathways a Success for Hip and Knee Replacements
06/20/2016
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value for...
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value for...
A...
06/20/2016
Journal of Clinical Pathways
Research in Review
Rectal Cancer Treatment Utilizing Chemotherapy and Radiation Therapy Improving Over Time
06/20/2016
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
A...
06/20/2016
Journal of Clinical Pathways
Research in Review
Blood Biomarkers Useful for Understanding NSCLC Prognosis
06/20/2016
A study of patients with inoperable non-small cell lung cancer (NSCLC) has found that certain blood biomarkers may have prognostic value and could enhance treatment decision-making for providers. To improve...
A study of patients with inoperable non-small cell lung cancer (NSCLC) has found that certain blood biomarkers may have prognostic value and could enhance treatment decision-making for providers. To improve...
A...
06/20/2016
Journal of Clinical Pathways
Research in Review
Omitting Radiotherapy for Breast Cancer Patients May Lead to Cost Savings
06/20/2016
Omitting radiotherapy as a part of standard care for women with low-risk luminal A (low-grade, estrogen receptor-positive) breast cancer would produce significant cost savings without adversely affecting outcomes,...
Omitting radiotherapy as a part of standard care for women with low-risk luminal A (low-grade, estrogen receptor-positive) breast cancer would produce significant cost savings without adversely affecting outcomes,...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
Lymph Node Ratio an Effective Indicator of Prognosis in Rectal Cancer
06/20/2016
Lymph node ratio (LNR) may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in clinical trials, claims a recently published...
Lymph node ratio (LNR) may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in clinical trials, claims a recently published...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
No Difference in Renal Function Decline With ACE inhibitors or ARBs for Diabetes
06/20/2016
A study comparing the effectivenesses of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for protecting patients with type 2 diabetes from renal function decline found no...
A study comparing the effectivenesses of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for protecting patients with type 2 diabetes from renal function decline found no...
A...
06/20/2016
Journal of Clinical Pathways
Editor's Page
Pathways for Improving Quality of Life
06/20/2016
Winston Wong, PharmD
As early detection of cancers and improved treatments continue to improve outcomes for patients with cancer, care providers have been able to increase their focus on the quality of life for patients with cancer who...
As early detection of cancers and improved treatments continue to improve outcomes for patients with cancer, care providers have been able to increase their focus on the quality of life for patients with cancer who...
As...
06/20/2016
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

June 2016 Volume 2

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use